IMPACT trial
Recent Biotech News: Altimmune’s Pemvidutide Advances in MASH, Emerging China Obesity Players, and Ipsen Phase 2 Setback
Altimmune; pemvidutide; MASH; Phase 2b; IMPACT trial; FDA; China obesity; Ipsen; Phase 2 fail
Actionable Insights Powered by AI
Altimmune; pemvidutide; MASH; Phase 2b; IMPACT trial; FDA; China obesity; Ipsen; Phase 2 fail